Positive Asthma Data Prompts Pulmagen To Seek Global Partner For CRTh2 Antagonist
Executive Summary
Following positive Phase II data from its CRTh2 antagonist PTR-36 in eosinophilic asthma patients, Pulmagen is looking for a late-stage development partner. PTR-36 is administered at a dose 'an order of magnitude lower' than a competing program from Novartis which is in Phase III, said the small UK firm.
You may also be interested in...
Chiesi Takes Aim At Next-Generation Eosinophilic Asthma Therapy
Chiesi may be coming late to the development of eosinophilic asthma therapies, but there are certain advantages associated with acquisition target Atopix Therapeutics’ potential products that could strengthen the specialty pharma's already significant presence in the asthma market.
Teijin turns to Pulmagen to plug respiratory pipeline gap
The pharmaceutical division of Teijin has acquired rights in Japan to Pulmagen Therapeutics' lead CRTh2 antagonist ADC3680, which it will develop initially for bronchial asthma.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.